CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

What’s New: Laid-Back Luxury: The Peaceful Charm of Bahamian May

Solésence Reports Record First Quarter 2025 Financial Results

Toll Brothers Announces Move-In Ready Homes Available in Mayfair Master Plan...

Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF...

Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering

Dalaboo Announces Launch of Practical AI Automation Services that Save Time,...

Healthy Choice Wellness Corp. Completes Second Tranche of Debt-for-Equity Conversion

Unisex Fragrances Gain Popularity Among Chinese Gen Z Consumers

NYO3, Global Leader in Krill Oil, Launches in Hong Kong’s Mannings...

FungaBeam Reviews: Advanced At-Home Nail Fungus LLLT Device for Toenail Health

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...